Subnets / SN68
NOVA SN68
NOVA (subnet 68) is a Bittensor subnet held by 3,689 unique coldkeys. Its liquidity pool holds 40.7k τ, with the alpha token trading at 0.0174 τ. Roughly 21% of tracked holders are in profit — most bought in above today's price. Seller exhaustion is elevated: 75% of recent sellers have emptied their wallets, thinning the supply overhang. Full insider flow, whale tracking and the complete proprietary factor set for NOVA are available to SubnetStats subscribers.
ALPHA PRICE
0.0174 τ
IN TAO
HOLDERS
3,689
UNIQUE COLDKEYS
POOL DEPTH
40.7k τ
TAO IN POOL
7D MOMENTUM
+6.2%
ALPHA vs TAO
Project activity
Huge thanks to @Ginkgo for giving @metanova_labs co-founders @pennapdr, @42salamandas, and @urdof07 a tour of their incredible robotics lab in Boston!
The scale of automation and experimental throughput they've achieved is remarkable.
The future of lab-in-the-loop discovery is
Watch full episode
@micaelabazo (Co-founder & CEO) and @pennapdr (Co-founder & CSO) of @metanova_labs sit down with @KhalaResearch @haitzu and @Lemz0x to discuss
- NOVA’s first lab results
- Competition participants behind NOVA
- How new drugs actually reach the market
- Why A
NOVA: Emission Split Update for Data Generation Fund
Owner 26% / Miners 33% / Validators 41%
With the launch of eTAO, subnet owners can now adjust how emissions are distributed. NOVA will be updating its split to allocate more resources toward what we believe is the highest-impa
Why are @AnthropicAI, @OpenAI, and @Google accelerating investment in AI drug discovery?
Is it:
Technical ambition? Drug discovery is one of the hardest real-world problems and a real stress test for AI capabilities.
Economic incentives? Capturing a share of pharma’s enormous
NOVA Hit-to-Lead Optimization Agent
In collaboration with @chutes_ai and @onepot_ai
We're developing a Hit-to-Lead optimization agent that integrates an algorithm developed by a NOVA Blueprint winner, extending NOVA's capabilities beyond hit discovery and into the iterative opt
Every major AI lab wants exposure to drug discovery. OpenAI now joins Anthropic, Google and co in acquisitions that give them access to pharma upside.
If Bittensor is to become the decentralized analogue it needs it too.
NOVA is that piece of the puzzle.
https://t.co/In4d3kDEPN
We’re harnessing competition to identify entry points in multibillion spaces for the development of new therapeutics.
@haitzu early on recognized the promise of our discovery model and of our partnership with @onepot_ai
AI drug discovery + robotics
Accelerating learning cycl
NOVA Blueprint: 678.5 Billion Possible Molecules
Last week, we upgraded Blueprint to Boltz-2-based scoring. This week, we're expanding the chemical search space by more than 11×.
Reactions: 5 → 44
Building blocks: 225K → 2.03M
Enumerable chemical space: 61.1B → 678.5B molecules
New research by @McKinsey shows discovery time cut by ~15-80% for AI-enabled candidates!
AI/ML drug discovery competitions are a powerful paradigm for advancing models and methods.
Congratulations to the teams involved including the pioneers who have helped establish this format. We’re excited to see it expanding and to be building on this approach with NOVA.
It’s only a matter of time before it becomes obvious to everyone that drug discovery is the best and potentially most rewarding use of compute and capital ↓
By then, we will have an unstoppable, increasingly automated system of incentive mechanisms connected with experimental va
New NOVA Blueprint winner
Delivers 7.02× PSICHIC inference speedup
from 214 → 1,502 protein–ligand pairs/sec
on an RTX 3090
That means the same inference workload can be completed with ~86% less time and compute costs, allowing substantially more chemical space to be evaluated
Build the next winning search algorithm:
Boltz-2 is coming to NOVA Blueprint.
The integration is now available for testing.
With this release, Boltz-2 scoring moves to a dedicated GPU oracle rather than running inside the miner sandbox. Competitors can query the oracle through
Mounjaro and Zepbound were 56% of @EliLillyandCo's 2025 revenue. @definiumtx's LSD tablet just got a 2nd FDA Breakthrough designation, this one for depression.
Both improve self-regulation, which can impact health, relationships, work and longevity.
Agency Therapeutics 🧵
The distance between intention and action is treated as a question of discipline.
GLP-1s, stimulants, psychedelics act on the biology of self-regulation.
Agency Therapeutics may be medicine's next major category.
Read: thesis, pharmacology, and how we're designing them ↓ https
https://t.co/bDVPWPA2vJ
NOVA Blueprint: Better Search Meets Better Models
Transitioning to Boltz-2-based scoring this week.
This matters because Boltz-2 gives Blueprint a richer scoring layer than PSICHIC. Boltz-2 is a structural biology foundation model that predicts biomolecular structure and bindin
Optimizing Discovery Through Adaptive Incentives
We track winning submissions and network-wide trends to generate the diversity and signal needed downstream.
We continuously tune parameters to guide the network through ultra-large chemical and biological spaces, producing rich
NOVA is a global market for virtual drug discovery: the first decentralized platform to coordinate continuous competitions to identify novel therapeutics and advance discovery tools.
3 competitions run in parallel across small molecules, nanobodies, and chemical search algorithm
NOVA targets keep getting more interesting
HDACs have been developed mainly as cancer targets. Studies published in 2026 point to a broader opportunity: selectively modulating the epigenetic machine that helps determine how the brain learns, adapts, and recovers.
A few findings
History in the making.
Huge congratulations to the teams at @moderna_tx and @Merck their individualized mRNA cancer therapy, which just became the first of its kind to succeed in a Phase 3 trial—meeting both recurrence-free survival and distant metastasis-free survival endpoints
NOVA Compound - more drug-like submissions
We’re adding the BRENK structural filter to our molecule validity criteria. The filter identifies and removes chemical structures associated with undesirable properties in drug development.
This further constrains the search beyond pre
NOVA Compound - 20x more molecules
As miner performance improved, Boltz-2 inference became one of the primary bottlenecks limiting how many molecules each miner could be evaluated on. We've reworked our inference parallelization strategy to support up to 20× more molecule evalua
NOVA Blueprint update
The next Blueprint winner will receive 30,000 $NOVA (~$144,000 USD).
For context, that's nearly 3× the recent #BELKA drug discovery competition and larger than @AnthropicAI one time Life Sciences hackathon.
We've intentionally set a very high bar for re
SELLERS DRAINED
75%
28D SELLERS EMPTIED OUT
CAPITULATION
-1.23
BOUNCE COMPOSITE (z)
HEAT 7D
0.19×
VOLUME ÷ POOL DEPTH
HOLDERS IN PROFIT
21%
TRACKED WALLETS · ENTRY BELOW PRICE
WHAT'S CARRYING THE PRICE · 30DMIXEDemission rank #14 · above the bar (rank 32)
30D RETURN
-12.8%
ALPHA vs TAO
WITHOUT CHAIN BUYS
-20.4%
SAME 30 DAYS, PROTOCOL BID REMOVED
CHAIN SHARE OF BUYING
100%
CHAIN BUYS vs TRADERS' NET
CHAIN BUYS / DAY
60 τ
PROTOCOL BUYING ITS ALPHA
See who's buying and selling NOVA — every trade classified miner / validator / owner / outsider, plus holder cost basis and the full 23-factor screener.
OPEN THE INSIDER TAPE →